Update on the Pathophysiological Role of Intracellular Signaling Pathways in Atherosclerotic Plaques and Ischemic Myocardium by Montecucco, Fabrizio et al.
104  Current Signal Transduction Therapy, 2012, 7, 104-110   
  1574-3624/12 $58.00+.00  ©2012 Bentham Science Publishers 
Update on the Pathophysiological Role of Intracellular Signaling Pathways 
in Atherosclerotic Plaques and Ischemic Myocardium 
Fabrizio Montecucco
1,*, Vincent Braunersreuther





1Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties, University of Geneva, 
Geneva, Switzerland; 
2Department of Internal Medicine, Adult Diabetes Centre, University of Genoa, Italy 
Abstract: Acute atherosclerotic complications, such as myocardial infarction, are often provoked by the rupture of an 
atherosclerotic plaque and the subsequent thrombotic occlusion of the arterial lumen, which interrupts the blood flow and 
renders ischemic the downstream peripheral tissue. Several inflammatory mediators (including cytokines, chemokines and 
matrix metalloproteases) have been shown to orchestrate common pathophysiological mechanisms regulating both plaque 
vulnerability and myocardial injury. In particular, the selective activation of certain protective intracellular signaling 
pathways might represent a promising target to reduce the dramatic consequences of an ischemic cardiac event. In the 
present review we will update evidence on the active role of intracellular kinase cascades (such as mitogen-activated 
protein kinases [MAPKs], Akt, Janus kinase [JAK]-signal transducer and activator of transcription [STAT]) to reduce the 
global patient vulnerability for acute myocardial infarction. 
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INTRODUCTION 
  Acute cardiac ischemic diseases, such acute myocardial 
infarction, have been estimated to become the first cause of 
mortality in the worldwide population before 2030 [1]. On 
the basis of these catastrophic projections, the scientific 
community will attempt to clarify the pathophysiological 
processes underlying the acute rupture of atherosclerotic 
plaques and prevent injury in the peripheral tissue. Since 
atherosclerosis has been largely defined as a systemic low-
grade inflammatory disease [2], different research strategies, 
targeting not only the “local” plaque instability, but also the 
systemic and “peripheral tissue” vulnerabilities, will be 
implemented [3, 4]. This “global” approach is expected to 
markedly improve the assessment of the risk and prognosis 
of an acute ischemic cardiovascular disease. In fact, when 
considered in a single issue, three determinants of 
cardiovascular vulnerability (involving the plaque, blood and 
peripheral tissue) have been proposed to possibly predict the 
severity of acute myocardial infarction and their sequelae [3, 
4]. In humans, several soluble inflammatory mediators, such 
as acute phase reactants (C-reactive protein [CRP]), 
cytokines (tumor necrosis factor [TNF]-alpha or interleukin 
[IL]-6), chemokines (CCL2 and CCL5) and matrix 
metalloproteinases ([MMPs], MMP-2, MMP-9), have been 
shown to be directly associated with both plaque and 
systemic vulnerabilities [5-11]. Although the expression of 
these mediators has been widely confirmed in atherosclerotic 
plaques and circulating blood [4, 6], recent studies support 
them to play a potential “dual” role as intraplaque or   
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systemic factors in atherogenesis [12]. On the basis of this 
multi-task approach, recent studies also focused on soluble 
inflammatory mediators to potentially increase the 
myocardial tissue resistance to the ischemic insult [13]. For 
instance, TNF-alpha (considered as a pro-inflammatory 
mediator increasing both plaque and blood vulnerabilities), 
has been shown to protect cardiomyocytes during the 
development of post-infarction heart failure [14]. Since 
TNF-alpha-mediated beneficial effect was observed at low 
concentrations [15, 16], these studies contributed to 
dramatically mitigate the ancient dichotomous concept 
(injury vs. protection) in atherosclerosis. We believe that it is 
time to become more “fluid” in exclusively considering 
biomarkers (reflecting the global vulnerability) as “good” or 
“bad” guys. Intriguingly, a single mediator (i.e. TNF-alpha) 
might activate opposite pathways within the plaque, the 
blood or the injured myocardium, thus supporting a not 
univocal role for this cardiovascular risk factor [14]. 
Therefore, in the next decade, the complex balance between 
pro- and anti-atherosclerotic mediators will probably shift to 
a matter of doses, timing, districts and signaling pathways.  
INTRACELLULAR PATHWAYS ARE ACTIVATED 
WITHIN ATHEROSCLEROTIC PLAQUES AND THE 
ISCHEMIC MYOCARDIUM 
  A limited number of studies investigated the role of 
intracellular signaling pathways in atherosclerotic plaque 
vulnerability  in vivo. Since atherosclerotic plaques are 
characterized by the presence of several vascular and 
inflammatory cells that have not been identified yet [5, 17], 
it is very difficult to identify the selective intracellular 
signaling pathways in such heterogeneous tissues. In 
particular, the recent discovery of different macrophage and 
lymphocyte subsets has further increased the complexity of 
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isolation of cell populations from atherosclerotic plaques 
remains very difficult [20], a potential ex vivo approach to 
assess the intraplaque phosphorylation of intracellular 
kinases still requires further improvements. Evidence from 
animal models prone to develop atherosclerosis and 
knockout for certain kinases has been recently provided [21, 
22]. On the other hand, several studies in rodents have 
demonstrated that the selective activation of some 
intracellular pathways is essential for saving the infarcted 
myocardium during reperfusion [23]. Evidence from animal 
studies has also shown a crucial role of mitogen-activated 
protein kinases (MAPKs) in the regulation of post-infarction 
cardiac remodeling [24]. In the following paragraphs, we 
will update evidence on the specific role of the most known 
intracellular signaling pathways regulating both plaque 
vulnerability and peripheral tissue resistance to ischemic 
insults. 
THE ROLE OF MITOGEN-ACTIVATED PROTEIN 
KINASES (MAPKs)  
  In mammals, MAPKs are intracellular enzymes which 
phosphorylate downstream proteins for transducing extra- 
cellular signals throughout the cytosol towads the nucleus 
[25]. As ubiquitous enzymes, they are known to coordinate 
several cell functions, such as proliferation, differentiation, 
motility, and survival [25]. The best known MAPKs are JNK 
(from 1 to 3), p38 (, , , and ) and ERK (from 1 to 5). 
Although their functions need to be further investigated, 
other proteins (such as ERK7/8, and Nemo-like kinase 
[NLK]), have been recently identified and included among 
the “classical” MAPKs. The MAPK cascade imply the 
phosphorylation of both upstream and downstream intra- 
cellular proteins [25]. The upstream enyzymes activating 
MAPKs are called “MAPK kinases”. The downstream 
substrates include members of a family of protein Ser/Thr 
kinases termed MAPK-activated protein kinases 
(MAPKAPKs) [25]. Therefore, in this complex network, the 
classical MAPK (JNK, p38MAPK and ERK) might 
differently regulate the cardiovascular vulnerability and 
cardiac resistance to ischemic injury. 
c-Jun NH(2)-Terminal Kinase (JNK) 
  The research group of Prof. Lüscher has recently showed 
that mice double knockout for ApoE and JNK2 develop 
reduced atherogenesis as compared to ApoE single knockout 
[26]. Intriguingly, this effect was observed only in animals 
lacking JNK2 and not JNK1. This protection was also 
confirmed by treating mice with the selective JNK inhibitor 
SP600125. The molecular mechanism underlying these 
results was indentified in the reduced differentiation of 
macrophages lacking JNK2 into foam cells [26]. The role of 
JNK2 activation in the early phases of atherogenesis was 
also investigated in single JNK2 knockout animals. 
Differently from wild type mice under high-cholesterol diet, 
hypercholesterolemia did not decrease the nitric oxide (NO) 
release from endothelial cells and the expression of 
antioxidants in mice JNK2-/-. These results suggest that 
JNK2 plays a pivotal role on endothelial dysfunction and 
oxidative stress in early atherogenesis. Furthermore, this 
article confirmed the inhibition of JNK2 as a promising 
therapeutic approach to reduce atherosclerosis at different 
stages [27]. The potential pro-atherosclerotic and pro-
inflammatory activities driven by JNK phosphorylation were 
also confirmed in vitro in human inflammatory [28] and 
vascular cells [29], suggesting a relevance for controlling 
this pathway in hyperinsulinemic states associated with 
atherosclerotic diseases. The JNK-dependent downstream 
signalization was further investigated in vivo in mice and in 
vitro in endothelial cells. In a mouse model of carotid 
arteries modified with a constrictive cuff, authors showed 
that a disturbed flow increased the expression of NF-B 
through the activation of JNK. Similarly, they observed that 
disturbed blood flow up regulated in vitro the expression of 
NF-B in endothelial cells via  JNK signaling [30]. If the 
JNK downstream pathways remain largely unknown, the 
potential upstream activation may require the deficiency   
of a protein mutated in the cancer-prone disease ataxia 
telangiectasia (ATM). In fact, its deletion in bone marrow 
cells might accelerate atherosclerosis in ApoE-/- mice [31].  
  The role of JNK activation in the ischemic myocardium 
is considered controversial. The phosphorylation of JNK in 
response to the cardiac preconditioning was shown by Haq 
and co-workers [32], but not confirmed by Nakano and 
colleagues [33]. This potential pathophysiological mechanism 
has been differently associated with cardiomyocyte protection 
[32, 34]. A recent study by Kaiser and co-workers, using 
both knockout mice for JNK1/2 and transgenic animals over 
expressing MKK7 (a kinase activating JNK) in the heart, 
failed to clarify this issue [35]. Although systemic JNK1/2 
activity was found positively associated with a reduction of 
myocardial injury, the selective over expression of JNK in 
the heart was shown to protect the myocardium from 
ischemia reperfusion. This paradoxical results highlighted 
the great complexity of JNK signaling and activation in 
myocardial reperfusion. 
p38 MAPK 
  The role of the activation of p38 MAPK pathway within 
the plaque appears controversial. Although evidence from 
p38 MAPK knockout animals is still lacking, some studies 
investigated more selective deletions of p38 MAPK and its 
pharmacological inhibition in atherogenesis. In a recent 
article, Tabas and co-workers investigated the role of 
deficiency in macrophage p38alpha MAPK in ApoE-/- mice 
under high-cholesterol diet. The authors found increased 
macrophage apoptosis, plaque necrosis and a reduction in 
collagen intraplaque content, suggesting the presence of 
more vulnerable lesions as compared to control ApoE-/- 
mice [36]. On the other hand, the pharmacological systemic 
inhibition of p38 MAPK (with the selective inhibitor 
SB203580) has been shown to increase pro-angiogenic cells 
and reduced the number of inflammatory cells in plaques   
of ApoE-/- mice. Confirming a crucial benefit from p38 
MAPK inhibition in atherogenesis, chronic treatment with 
SB203580 reduced size and progression of atherosclerotic 
lesions [37]. The promising results of p38 MAPK inhibition 
in mouse atherosclerotic plaques were partially confirmed by 
using magnetic resonance imaging (MRI) with ultra small 
super paramagnetic iron oxide (USPIO) contrast agents. The 
uptake of these iron particles within the aortas (typically 
done by intraplaque resident macrophages) was attenuated 
by the treatment with another p38 MAPK inhibitor (SB-
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Importantly, the upstream pathways governing p38 MAPK 
activation were recently investigated. Mice ApoE knockout 
and Grb2 heterozygous (a ubiquitous protein activating 
downstream MAPK, such as JNK and p38 MAPK) have 
been shown to develop a reduced lesion formation as 
compared to ApoE single knockout mice [39]. In vitro 
experiments using bone marrow-derived macrophages 
showed that Grb2 was necessary for the activation of MAPK 
in response to oxidized low density lipoprotein (oxLDL) 
stimulation [39]. On the other hand, the potential role of the 
apoptosis signal-regulating kinase 1 (ASK1), known to be 
upstream the MAPKs and thus, called as “MAPK kinase 
kinase”, has been recently investigated in a knockout model 
of atherosclerosis. ASK1 and ApoE double knockout mice 
under high-cholesterol diet had accelerated atherogenesis as 
compared with ApoE single knockout animals. This effect 
was associated with a reduction in the macrophage apoptotic 
rate within atherosclerotic plaques. The relevance for this 
protein in hyperlipidemia-induced atherogenesis was 
confirmed by comparing atherosclerotic size in animals 
transplanted with ASK1 (-/-) or wild type bone marrow cells. 
Increased lesion size was observed in mice receiving ASK1 
(-/-) bone marrow as compared to wild type. ASK1-
dependent pathway might be protective in hyperlipidemia-
induced atherosclerosis [22]. However, these beneficial 
effects in atherosclerotic size might be counterbalanced by a 
marked increase of macrophage apoptosis, which could favor 
the development of a bigger necrotic core and increase 
plaque vulnerability. In vitro, p38 MAPK activation has been 
shown to favor the up regulation of adhesion molecules 
(ICAM-1 and VCAM-1) on endothelial cells [40] and 
leukocyte migration towards pro-atherosclerotic chemokines 
[41]. Therefore, these studies confirmed the risky activities 
of p38 MAPK in atherosclerotic inflammation. Several 
evidences are available on the role of p38 MAPK activation 
in cardioprotection from ischemia and reperfusion injury. 
During the last decade, three different review articles 
summarized the controversial results on the role of this 
kinase in cardioprotection [42-44]. Although several limitations 
(due to the variety of inhibitors for multiple isoforms of p38 
MAPK) exist [44], the inhibition of p38 MAPK pathway has 
been shown to improve the left ventricular matrix remodeling 
and cell survival after ischemic events [45, 46]. The down- 
stream targets within cardiomyocytes potentially improved 
by inhibition p38 MAPK have been indicated as the 
stabilization of the cytoskeleton, the improvement of 
mitochondria functions and reduction in gap junction 
permeability [47-49]. Since p38 MAPK activation during 
reperfusion after sustained ischemia might be characterized 
by a biphasic phosphorylation [50], potential dichotomous 
activities might be hypothesized. However, since this particular 
activation was also observed for other kinases (such as ERK 
and Akt), further studies are needed to better understand the 
complex connections between these redundant pathways.  
Extracellular Regulated Kinase (ERK) 
  Despite huge amount of in vitro experiments, evidence 
for the role of ERK activation in atherosclerotic plaque 
vulnerability in vivo is still lacking. In vitro, ERK has been 
shown to regulate several functions of inflammatory and 
vascular cells in atherogenesis. For instance, ERK activation 
is crucial for leukocyte migration in a pro-atherosclerotic 
microenvironment [41, 51]. Importantly, pre-incubation with 
statins has been shown to reduce ERK 1/2 phosphorylation 
and associated pro-inflammatory functions in response to   
C-reactive protein (CRP) in human monocytes [51]. 
Confirming the pro-inflammatory relevance of ERK 
activation, recent findings also indicate that ERK1/2 
pathway is crucial for pro-thrombotic in vitro activities of 
receptor activator of nuclear factor B ligand (RANKL) in 
macrophages [52]. Accordingly, we recently showed that 
that ERK1/2 activation is pivotal for the neutrophilic release 
of matrix metalloproteases (MMPs) in response to RANKL 
[53]. Since MMPs are considered to increase plaque 
vulnerability [54], the potential role of ERK pathway in their 
release from other cells resident within atherosclerotic 
plaques has been also investigated. The activation of ERK 
pathway has been shown to regulate the expression in vitro 
of MMP-9 in vascular smooth muscle cells (SMCs) in 
response to different pro-atherosclerotic stimuli [55, 56]. 
Finally, ERK phosphorylation was required to activate 
endothelial cells in several culture models [57-59]. All these 
in vitro studies indicated that ERK activation is essential for 
promoting atherogenesis and increasing plaque vulnerability. 
A strong agreement by the scientific community supports 
this conclusion. On the other hand, some controversies exist 
on the role of ERK pathway in cardioprotection. In normal 
conditions, the activation of Raf/MEK/ERK1/2 signaling in 
cardiomyocytes mediates cardiac hypertrophy (a major risk 
factor for the development of arrhythmias, heart failure and 
sudden death) [60]. On the other hand, ERK activation might 
also protect the ischemic hearts from cell death and 
reperfusion injury [60]. Evidence from in vivo studies 
partially confirms the beneficial role of cardiac ERK 
phosphorylation in acute myocardial infarction [61]. 
However, the entity of ERK phosphorylation does not 
correlate with the infarct size in mice [62], indicating that 
this process might be influenced by post-infarction 
infiltration of inflammatory cells within the infarcted 
myocardium. The early activation of ERK and Akt has been 
included in the more complex Reperfusion Injury Salvage 
Kinase (RISK) pathway [63], which is well-accepted for 
mediating cardiac protection. Downstream players of this 
pathway are still not clarified yet. Intracellular organelles 
(such as mitochondria), gap junctions and apoptotic 
modifications represent the most promising mechanism to 
identify the RISK pathway targets mediating benefits on 
ischemic cardiomyocytes [23]. 
THE ROLE OF SERINE/THREONINE KINASE/ 
PROTEIN KINASE B (AKT) 
  Other kinases, such as Akt, have been recently 
investigated in atherogenesis and plaque vulnerability with 
resulting opposite activities as compared to MAPKs. Akt 
(also called protein kinase B) is a family of serine/threonine 
kinases abundantly expressed in both cardiovascular and 
inflammatory cells [64, 65]. Akt activation is mediated by an 
upstream cascade involving phosphatidylinositol-3’ kinase 
(PI3-k) that generates phosphatidylinositol-3’,4’,5’-phosphate 
(PIP3), which in turn activates phosphoinositide-dependent 
kinase 1 (PDK1). This kinase directly phosphorylates Akt 
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vitro studies on the role of the Akt-dependent pathway in 
plaque vulnerability. Preliminary studies indicated that Akt 
activation might protect plaques from rupture. Interestingly, 
the blockade of Akt1 abrogates the beneficial proliferation 
and migration of vascular smooth muscle cells. This effect 
was confirmed in vivo in Akt1 and ApoE double knockout 
mice, which developped more vulnerable atherosclerotic 
plaques [21]. Therefore, this study suggests a protective role 
for Akt activation in advanced atherosclerosis [21]. 
Conversely, the activation of Akt in inflammatory cells was 
also associated with the reduction of their apoptosis and the 
functional abrogation of the mediators sustaining plaque 
inflammation [67, 68]. Surprisingly, Yancey and co-workers 
confirmed that the reduction in macrophage Akt 
phosphorylation was associated with an increase in 
intraplaque apoptosis in LDLR-/- mice transplanted with 
LRP-1-/- bone marrow [69]. Interestingly, this study 
suggested a paradoxical pro-inflammatory mechanism (due 
to the formation of a bigger necrotic core) increasing plaque 
vulnerability also when the function of inflammatory cells is 
neutralized.  
  Since the activation of Akt pathway has been shown to 
promote macrophage migration and survival also after an 
acute myocardial infarction, Li and co-workers recently 
investigated the interesting cross-talk between inflammatory 
cells and cardiomyocytes during the post-infarction 
reperfusion in mice lacking Akt2 [70]. The infarcted 
myocardium from Akt2 knockout mice revealed an increased 
macrophage infiltration [70]. This increased inflammation 
was associated with larger infarct size and reduced cardiac 
function as compared to wild type mice [70], reflecting the 
confounding effect of Akt2 deficiency on cardiomyocyte 
injury. 
  While Akt1 activation has been shown to regulate 
physiologic cardiac hypertrophy in response to the GH-IGF-
1 [71, 72], Akt2 phosphorylation is crucial to improve 
cardiomyocyte survival [72]. Thus, mainly Akt2 instead of 
Akt1 might be considered as an element of the RISK 
pathway. This direct beneficial effect in cardiomyocytes was 
particularly observed in response to myocardial infarction 
[72] and might related with the downstream inhibition of 
pro-apoptotic mediators, such as BAD, Bax and Caspase-9 
[73-75]. It has been hypothesized that Akt2 activation in 
cardiomyocytes might also interfere with p38 MAPK and 
JNK pathways [76]. However, further studies are required to 
better clarify this issue. In fact, the inhibition of Akt1/2 was 
also found in cardiomyocytes cultured in the presence of a 
stress inducer of the endoplasmic reticulum, suggesting that 
this pathway might be involved in the regulation of cell 
dysfunction [77]. The association between ER stress and Akt 
inhibition was also confirmed in vivo in a mouse model of 
myocardial infarction [77]. However, the molecular 
mechanisms underlying this effect have to be identified. 
THE ROLE OF JANUS KINASE (JAK)-SIGNAL 
TRANSDUCER AND ACTIVATOR OF TRANS- 
CRIPTION (STAT) PATHWAY 
  Since JAK/STAT activation is directly mediated by the 
homo- or hetero-dimerization of transmembrane receptors, 
this intracellular pathway represents one among the fastest 
transduction pathways for the salvage of cardiomyocytes 
from the sudden ischemic insults [78]. The direct 
phosphorylation of JAK induced by the intracellular domain 
of the transmembrane receptor is the main determinant of 
this immediate activation [78]. Once phosphorylated, JAK 
activate back the receptor to adapt docking sites for the 
cytosolic STAT protein. At this stage, JAK is able to 
phosphorylate STAT on the tyrosine residue (Tyr 705). Next, 
the phosphorylated STAT monomer undergoes to homo- or 
hetero-dimerization and becomes capable of dissociating 
form the receptor. Then, STAT is able to translocate into the 
nucleus for binding DNA and triggering gene expression 
[78]. JAK might also phosphorylate STAT in a specific 
serine residue (Ser 727), resulting in final transcriptional 
activities [78]. Depending on the specific JAK and STAT 
subtypes that have been identified in different tissues [79, 
80], several inflammatory mediators have been shown to 
activate this pathway. In particular, interleukin (IL)-6, 
oncostatin M, and cardiotrophin-like cytokine 1 (CT-1) have 
been described as the most-known inducers of JAK-STAT 
pathway in the heart [81]. Importantly, these mediators were 
also capable of inducing opposite effects on cardiomyocyte 
survival, depending on the activation of different STAT 
family members. While the activation of STAT1 is believed 
to induce cardiomyocyte death, concomitant increase in 
STAT3 activity has been shown to increase cardioprotection 
in vitro and in vivo [82, 83]. These studies further complicate 
the role of JAK-STAT pathway in the cardioprotection from 
the ischemic injury. This finding was also confirmed by the 
lack of activity of the selective JAK inhibitor (AG-490)   
in modifying the ischemia/reperfusion injury in vivo [84]. 
Thus, although the JAK-STAT3 pathway has been included 
as a key component of the Survivor Activating Factor 
Enhancement (SAFE) pathway for cardiomyocytes [63], this 
univocal interpretation should be now considered as more 
controversial. This aspect was particularly important for 
clarifying the paradoxical role of certain pro-inflammatory 
mediators (such as TNF-alpha or IL-6) in both post-ischemic 
myocardial injury and plaque vulnerability [85]. In fact, pro-
inflammatory cytokines have been recently shown to up 
regulate the expression of suppressors of cytokine signaling 
(SOCS) proteins (direct negative regulators of JAK/STAT 
pathways) in vascular smooth muscle cells (VSMCs) and 
macrophages  in vitro and in vivo (ApoE-/- mice). The up 
regulation of SOCS, associated with the coherent 
suppression of STAT activation, has been shown to 
exacerbate atherosclerotic inflammation and progression 
[86]. In contrast with previously shown evidence on 
cardiomyocytes, this study indicates that pro-inflammatory 
mediators tend to inhibit the potential protective role of 
JAK-STAT pathway within atherosclerotic plaques. On the 
other hand, IL-6 (an inducer of vascular smooth muscle   
cells [VSMC] proliferation and release of leukocyte 
chemoattractants), has been shown to partially activate the 
JAK/STAT3 pathway [87]. Differently from the study by 
Ortiz-Muñoz and co-workers, this study suggests a potential 
active role of the JAK/STAT pathway in atherogenesis   
[87]. Since several cell subsets play a crucial activity   
within atherosclerotic plaques, we believe that too many 
confounders might interfere with the final activity (pro- vs. 
anti-atherosclerosis) of a single intracellular pathway. Thus, 
the role of JAK-STAT pathway in atherosclerotic plaque 
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CONCLUSION 
 Intensive  investigations  in vitro and in vivo have been 
performed to better understand the selective activities of 
intracellular kinases in atherosclerosis. Given the great 
number of cell populations involved in plaque vulnerability 
and post-infarction cardiac injury, this approach implied as a 
considerable amount of work by several research groups. 
This strong effort resulted in the identification of certain 
promising candidates to selectively reduce plaque 
vulnerability and cardiac injury (Table 1). Despite some 
controversies, MAPK, Akt and JAK-STAT pathways can 
actively influence both atherogenesis and cardiac damage 
and repair. However, the identification of a common 
pathway mediating beneficial effects in both conditions has 
to be performed. Therefore, since evidence for these proteins 
as promising therapeutic targets has been established only in 
cellular and animal models, a strong work is waiting for 
researchers to translate this exciting strategy to human 
beings. Several limitations (mainly due to the ubiquitous 
distribution of these proteins and high toxicity of the 
pharmacological kinase inhibitors) are still present and might 
delay the relevant therapeutic impact of this approach. Thus, 
we recommend as a priority to improve knowledge on more 
selective isoforms of these intracellular kinases and their 
functions in atherosclerosis. 
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